When you look at a comparison between PRICERA™ and NR (Nicotinamide Riboside) and NMN (Nicotinamide Mononucleotide) –
Pricera comes out the clear winner!
| PRICERA™ clinically proven to outperform both NR* and NMN** | |||
| PRICERA™ | NR | NMN | |
| Increases NAD+ | ✔ | ✔ | ✔ |
| Simultaneously increases ATP, NAD+, and GSH | ✔ | ✖ | ✖ |
| Utilizes the dominant pathway for NAD+ synthesis | ✔ | ✖ | ✖ |
| Utilizes shunt pathway for NAD+ synthesis | ✖ | ✔ | ✔ |
| Stable in most applications | ✔ | ✖ | ✖ |
| Orally bioavailable (high amounts end up in blood) | ✔ | ✖ | ✖ |
| Survives digestive process intact | ✔ | ✖ | ✖ |
| *NR – Nicotinamide Riboside **NMN – Nicotinamide Mononucleotide | |||
Supporting Documentation:
- Avery B (Department of Pharmaceutics and Drug Delivery, The University of Mississippi), 2017. Pharmacokinetic Analysis of Plasma Nicotinamide and 1-Methyl Nicotinamide Concentrations in Toxicokinetic Study of NIAGEN (Nicotinamide Riboside).Study Report No AV151003. Unpublished Study Report, 9 pp.
- Liu L. et al. Quantitative analysis of NAD synthesis-breakdown fluxes. CellMetab.27, 1067–1080 (2018).
- Xue, YQ, Increasing NAD level by D-ribose and its combinations. PCT/US2019/031889 patent pending.
- https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ19-0313/_article
- https://www.nature.com/articles/s41467-018-03421-7